¿Cómo se compara el ratio PE de 950 con empresas similares?

950 es cara según su ratio Price-To-Earnings (11.4x) en comparación con la media de empresas similares (8x).

¿Cómo se compara el ratio PE de 950 con el de otras empresas de la industria HK Pharmaceuticals ?

950 es cara en función de su ratio Price-To-Earnings (11.4x) en comparación con la media de la industria Hong Kong Pharmaceuticals (8x).

¿Cuál es el ratio PE de 950 comparado con su ratio PE justo? Este es el ratio PE esperado teniendo en cuenta las estimaciones de crecimiento de ingresos de la empresa, los márgenes de beneficios y otros factores de riesgo.

Datos insuficientes para calcular el ratio justo Price-To-Earnings de 950 para análisis de valoración.

¿Cuál es el precio justo de 950 si consideramos sus flujos de caja futuros? Para esta estimación utilizamos un modelo de flujo de caja descontado.

950 (HK$1.22) cotiza por encima de nuestra estimación de [[valor justo]] (HK$0.66)

¿Cuál es la estimación de los analistas a 12 meses y, existe una confianza estadística en el precio objetivo de consenso?

Datos insuficientes para mostrar el pronóstico de precios.

Lee's Pharmaceutical Holdings (SEHK:950) - Cotización, noticias y análisis

Resumen de acción 950

Lee's Pharmaceutical Holdings Limited, sociedad de cartera de inversiones, desarrolla, fabrica, comercializa y vende productos farmacéuticos principalmente en la República Popular China. Saber más

Análisis fundamental de 950
Puntuación del snowflake
Valoración	0/6
Crecimiento futuro	0/6
Rendimiento pasado	4/6
Salud financiera	5/6
Dividendos	1/6

Recompensas

Los beneficios aumentaron un 61.9% el pasado año

Análisis de riesgos

Los beneficios han disminuido un 14.9% al año en los últimos 5 años

No tiene una capitalización de mercado significativa (HK$718M)

Competidores de Lee's Pharmaceutical Holdings Limited

Lansen Pharmaceutical Holdings

SEHK:503

HK$750.6m

Jilin Province Huinan Changlong Bio-pharmacy

SEHK:8049

HK$767.5m

Zhongzhi Pharmaceutical Holdings

SEHK:3737

HK$820.4m

Pak Fah Yeow International

SEHK:239

HK$766.6m

Historial de precios y rendimiento

Resumen de todos los máximos históricos, cambios y caídas de precios de Lee's Pharmaceutical Holdings
Precios históricos de las acciones
Precio actual de la acción	HK$1.22
Máximo en las últimas 52 semanas	HK$1.75
Mínimo de 52 semanas	HK$1.00
Beta	0.87
1Cambio en 1 mes	-2.40%
Variación en 3 meses	-0.81%
Cambio de 1 año	-2.40%
3Variación en 3 años	-64.64%
Variación en 5 años	-68.96%
Variación desde la OPV	134.62%

Noticias y actualizaciones recientes

Lee's Pharmaceutical Holdings' (HKG:950) Earnings Are Weaker Than They Seem

Sep 04

Recent updates

Lee's Pharmaceutical Holdings' (HKG:950) Earnings Are Weaker Than They Seem

Sep 04

There's Reason For Concern Over Lee's Pharmaceutical Holdings Limited's (HKG:950) Price

Aug 07

Lee's Pharmaceutical Holdings (HKG:950) Has Affirmed Its Dividend Of HK$0.01

May 21

Optimistic Investors Push Lee's Pharmaceutical Holdings Limited (HKG:950) Shares Up 28% But Growth Is Lacking

Dec 20

Can Mixed Fundamentals Have A Negative Impact on Lee's Pharmaceutical Holdings Limited (HKG:950) Current Share Price Momentum?

Mar 17

Should You Buy Lee's Pharmaceutical Holdings Limited (HKG:950) For Its 0.9% Dividend?

Feb 22

What Type Of Returns Would Lee's Pharmaceutical Holdings'(HKG:950) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

Jan 29

What Type Of Shareholders Own The Most Number of Lee's Pharmaceutical Holdings Limited (HKG:950) Shares?

Jan 12

Rentabilidad de los accionistas

	950	HK Pharmaceuticals	Mercado HK
7D	-4.7%	0.07%	-0.6%
1Y	-2.4%	-10.2%	9.6%

Rentabilidad vs. Industria: 950 superó a la industria Hong Kong Pharmaceuticals, que obtuvo un rendimiento del -10.2% el año pasado.

Rentabilidad vs. Mercado: 950 obtuvo unos resultados inferiores a los del mercado Hong Kong, que fueron del 9.6% el año pasado.

Volatilidad de los precios

Is 950's price volatile compared to industry and market?
950 volatility
950 Average Weekly Movement	6.9%
Pharmaceuticals Industry Average Movement	6.8%
Market Average Movement	8.9%
10% most volatile stocks in HK Market	19.2%
10% least volatile stocks in HK Market	4.3%

Precio estable de las acciones: 950 no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de 950 (7%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1994	993	n/a	www.leespharm.com

Lee's Pharmaceutical Holdings Limited, un holding de inversiones, desarrolla, fabrica, comercializa y vende productos farmacéuticos principalmente en la República Popular China. Sus actividades se centran en diversas enfermedades, como las cardiovasculares, la salud de la mujer, la pediatría, las enfermedades raras, la oncología, la dermatología y la obstetricia. Opera a través de los segmentos de Productos Patentados y Genéricos, y Productos Bajo Licencia.

Resumen de fundamentos de Lee's Pharmaceutical Holdings Limited

¿Cómo se comparan los beneficios e ingresos de Lee's Pharmaceutical Holdings con su capitalización de mercado?
Estadísticas fundamentales de 950
Capitalización bursátil	HK$718.38m
Beneficios(TTM)	HK$63.06m
Ingresos (TTM)	HK$1.20b

11.4x

Ratio precio-beneficio (PE)

0.6x

Ratio precio-ventas (PS)

¿Está 950 sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de 950
Ingresos	HK$1.20b
Coste de los ingresos	HK$581.63m
Beneficio bruto	HK$617.44m
Otros gastos	HK$554.38m
Beneficios	HK$63.06m

Últimos beneficios comunicados

Jun 30, 2024

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	0.11
Margen bruto	51.49%
Margen de beneficio neto	5.26%
Ratio deuda/patrimonio	14.2%

¿Cómo se ha desempeñado 950 a largo plazo?

Ver rendimiento histórico y comparativa

Dividendos

2.5%

Rentabilidad actual por dividendo

28%

Ratio de pagos

Resumen de acción 950

Recompensas

Análisis de riesgos

Competidores de Lee's Pharmaceutical Holdings Limited

SEHK:503

HK$750.6m

SEHK:8049

HK$767.5m

SEHK:3737

HK$820.4m

SEHK:239

HK$766.6m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Investor sentiment improves as stock rises 16%

Board Member recently bought HK$66k worth of stock

Lee's Pharmaceutical Holdings' (HKG:950) Earnings Are Weaker Than They Seem

First half 2024 earnings released: EPS: HK$0.11 (vs HK$0.027 in 1H 2023)

First half dividend of HK$0.02 announced

Lee's Pharmaceutical Holdings Limited to Report First Half, 2024 Results on Aug 28, 2024

Recent updates

Investor sentiment improves as stock rises 16%

Board Member recently bought HK$66k worth of stock

Lee's Pharmaceutical Holdings' (HKG:950) Earnings Are Weaker Than They Seem

First half 2024 earnings released: EPS: HK$0.11 (vs HK$0.027 in 1H 2023)

First half dividend of HK$0.02 announced

Lee's Pharmaceutical Holdings Limited to Report First Half, 2024 Results on Aug 28, 2024

There's Reason For Concern Over Lee's Pharmaceutical Holdings Limited's (HKG:950) Price

Lee's Pharmaceutical Holdings Limited Announces the First Patient Has Been Enrolled in A Phase I Clinical Trial to Receive Au409 At Queen Mary Hospital, Hong Kong

Board Member recently bought HK$59k worth of stock

Board Member recently bought HK$117k worth of stock

Lee's Pharmaceutical Holdings Limited Appoints Huang Zuie Chin as A Non-Executive Director

Board Member recently bought HK$120k worth of stock

Board Member recently bought HK$61k worth of stock

Lee's Pharmaceutical Holdings (HKG:950) Has Affirmed Its Dividend Of HK$0.01

Upcoming dividend of HK$0.01 per share

Board Member recently bought HK$130k worth of stock

Less than half of directors are independent

Final dividend of HK$0.01 announced

Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 22, 2024

Full year 2023 earnings released: EPS: HK$0.028 (vs HK$0.087 in FY 2022)

Lee's Pharmaceutical Holdings Limited Proposes Ordinary Final Dividend for the Year Ended 31 December 2023, Payable on 17 June 2024

Lee's Pharmaceutical Holdings Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

Board Member recently bought HK$123k worth of stock

New minor risk - Market cap size

Board Member recently bought HK$75k worth of stock

Investor sentiment improves as stock rises 15%

Optimistic Investors Push Lee's Pharmaceutical Holdings Limited (HKG:950) Shares Up 28% But Growth Is Lacking

Investor sentiment improves as stock rises 18%

Board Member recently bought HK$50k worth of stock

Board Member recently bought HK$113k worth of stock

Senior Adviser & Non-Executive Director recently bought HK$347k worth of stock

Investor sentiment improves as stock rises 17%

Senior Adviser & Non-Executive Director recently bought HK$110k worth of stock

Senior Adviser & Non-Executive Director recently bought HK$76k worth of stock

Investor sentiment improves as stock rises 18%

Price target decreased by 55% to HK$1.10

Lee's Pharmaceutical Holdings Limited Announces Interim Dividend for the Six Months Ended June 30, 2023, Payable on 04 October 2023

First half 2023 earnings released: EPS: HK$0.027 (vs HK$0.048 in 1H 2022)

New minor risk - Market cap size

Lee's Pharmaceutical Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2023

Lee's Pharmaceutical Holdings Limited to Report First Half, 2023 Results on Aug 30, 2023

Lee's Pharmaceutical Holdings' (HKG:950) Dividend Is Being Reduced To HK$0.01

Lee's Pharmaceutical Holdings Limited Appoints Cheang Yee Wah, Eva as Independent Non-Executive Director

Upcoming dividend of HK$0.01 per share at 1.3% yield

Lee's Pharmaceutical Holdings' (HKG:950) Dividend Is Being Reduced To HK$0.01

Full year 2022 earnings released: EPS: HK$0.087 (vs HK$3.38 in FY 2021)

Lee's Pharmaceutical Holdings Limited Announces Inclusion of Treprostinil Injection, Teglutik and Trittico in the National Reimbursement Drug List

Third quarter 2022 earnings released: EPS: HK$0.058 (vs HK$0.024 in 3Q 2021)

Price target decreased to HK$1.80

Less than half of directors are independent

Lee's Pharmaceutical Holdings Limited to Report Q3, 2022 Results on Nov 17, 2022

Lee's Pharmaceutical Holdings Limited Announces Completion of Patient Enrolment for A Phase III Clinical Trial of Intrarosa

Price target decreased to HK$1.80

Upcoming dividend of HK$0.01 per share

Lee's Pharmaceutical Holdings' (HKG:950) Dividend Is Being Reduced To HK$0.01

Lee's Pharmaceutical Holdings Limited Announces Interim Dividend for the Six Months Ended June 30, 2022, Payable on September 27, 2022

Second quarter 2022 earnings released: EPS: HK$0.014 (vs HK$3.59 in 2Q 2021)

Lee's Pharmaceutical Holdings Limited to Report First Half, 2022 Results on Aug 26, 2022

Lee's Pharmaceutical Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2022